AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10803996 — intervention group
Group type: COMPARATOR
Intervention: No preoperative urinary bladder catheterization (without Foley)
Number of subjects: 261
Study 10803996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without Foley)
Number of subjects: 261
Study 8829879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (2, 4, and 6 micrograms min‐1 kg‐1)
Number of subjects: 8
Study 8829879 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (0.5, 1, and 2 micrograms min‐1 kg‐1)
Number of subjects: 8
Study 8829879 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of dobutamine and sodium nitroprusside
Number of subjects: 8
Study 1630677 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis with SK and rtPA
Number of subjects: 56
Study 1630677 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard electrocardiogram
Number of subjects: 56
Study 6437840 — intervention group
Group type: EXPERIMENTAL
Intervention: DHM 32-550 (high dosage)
Number of subjects: 5
Study 6437840 — intervention group
Group type: EXPERIMENTAL
Intervention: DHM 32-550 (low dosage)
Number of subjects: 5
Study 6437840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31077081 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 10472
Study 29183908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 562
Study 29183908 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment arm
Number of subjects: 562
Study 27428501 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Shear Rate Therapy (ISRT)
Number of subjects: 14
Study 25377067 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment to suppress all electrographic seizure activity
Number of subjects: 172
Study 25377067 — intervention group
Group type: COMPARATOR
Intervention: No treatment of electroencephalographic status epilepticus
Number of subjects: 172
Study 22160383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-based treatment before and after autologous stem cell transplantation (arm B)
Number of subjects: 354
Study 22160383 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without bortezomib (arm A)
Number of subjects: 354
Study 20071701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 903
Study 20071701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 903
Study 20071701 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 903
Study 20071701 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to Ustekinumab after Etanercept
Number of subjects: 903
Study 18037442 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training (16 group training sessions)
Number of subjects: 66
Study 18037442 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (control group)
Number of subjects: 66
Study 16128674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 1675
Study 16128674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1675
Study 12138951 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative procedures
Number of subjects: 10
Study 12138951 — intervention group
Group type: COMPARATOR
Intervention: Sham procedures
Number of subjects: 10
Study 10431345 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX-GI (3.3% CHX gluconate)
Number of subjects: 19
Study 10431345 — intervention group
Group type: COMPARATOR
Intervention: GI cement without CHX
Number of subjects: 19
Study 10431345 — intervention group
Group type: COMPARATOR
Intervention: Professional tooth cleaning only
Number of subjects: 19
Study 7594088 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin alone (group I, 14 patients)
Number of subjects: 28
Study 7594088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin with oral hydralazine (75 mg four times a day, group II, 14 patients)
Number of subjects: 28
Study 1988576 — intervention group
Group type: EXPERIMENTAL
Intervention: E 50 mg/m2 and prednisolone (LEP)
Number of subjects: 211
Study 1988576 — intervention group
Group type: COMPARATOR
Intervention: E 100 mg/m2 and prednisolone (HEP)
Number of subjects: 211
Study 7051365 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz
Number of subjects: 30
Study 7051365 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 30
Study 31876109 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT)
Number of subjects: 5
Study 30113994 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent circuit training program (EXER)
Number of subjects: 54
Study 30113994 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONTROL)
Number of subjects: 54
Study 28162999 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab 10 mg/kg
Number of subjects: 951
Study 28162999 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 951
Study 26829218 — intervention group
Group type: EXPERIMENTAL
Intervention: Metroplasty with intrauterine palpator (group T)
Number of subjects: 90
Study 26829218 — intervention group
Group type: COMPARATOR
Intervention: Metroplasty without intrauterine palpator (group C)
Number of subjects: 90
Study 24372439 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored oral health educational programme
Number of subjects: 87
Study 24372439 — intervention group
Group type: COMPARATOR
Intervention: Standard oral health educational programme
Number of subjects: 87
Study 22916669 — intervention group
Group type: EXPERIMENTAL
Intervention: TMDes
Number of subjects: 152
Study 22916669 — intervention group
Group type: COMPARATOR
Intervention: Stabilization splint
Number of subjects: 152
Study 22916669 — intervention group
Group type: COMPARATOR
Intervention: Jaw exercise regimen
Number of subjects: 152
Study 19593733 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach (PA) repair
Number of subjects: 91
Study 19593733 — intervention group
Group type: COMPARATOR
Intervention: Anterior approach (AA) repair
Number of subjects: 91
Study 17453603 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD probands
Number of subjects: 186
Study 17453603 — intervention group
Group type: COMPARATOR
Intervention: Control probands
Number of subjects: 186
Study 17453603 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects using to get high
Number of subjects: 186
Study 17453603 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects using alcohol
Number of subjects: 186
Study 15823119 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 78
Study 15823119 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 78
Study 11963450 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 0
Study 11963450 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study 9417158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous A1PI (60 mg/kg) infused on days 0, 4, 7, and 14
Number of subjects: 106
Study 9417158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 7639298 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.2 mg/ml twice daily for five days)
Number of subjects: 64
Study 7639298 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autograft
Number of subjects: 64
Study 7639298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (balanced saline solution)
Number of subjects: 64
Study 2231212 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance indomethacin therapy (0.2 mg/kg/day for 5 days)
Number of subjects: 39
Study 2231212 — intervention group
Group type: COMPARATOR
Intervention: Standard indomethacin therapy (three doses) followed by placebo (equivalent volume for 5 days)
Number of subjects: 39
Study 487757 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective induction of labour at 39-40 weeks
Number of subjects: 228
Study 487757 — intervention group
Group type: COMPARATOR
Intervention: Expectant management until 41 weeks
Number of subjects: 228
Study 487757 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective induction of labour
Number of subjects: 228
Study 487757 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 228
Study 31726882 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release calcifediol (ERC)
Number of subjects: 1000
Study 31726882 — intervention group
Group type: COMPARATOR
Intervention: Paricalcitol
Number of subjects: 1000
Study 31759372 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated educational program (four 60-min sessions, one session per week)
Number of subjects: 64
Study 28762081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 144
Study 28762081 — intervention group
Group type: COMPARATOR
Intervention: Previous standard-of-care treatments
Number of subjects: 144
Study 26200716 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation (tDCS) over left and right hemisphere
Number of subjects: 0
Study 26200716 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation over left and right hemisphere
Number of subjects: 0
Study 23856660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide plus intravenous B-vitamins
Number of subjects: 500
Study 23856660 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide plus placebo
Number of subjects: 500
Study 23856660 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T or A1298C gene variant
Number of subjects: 500
Study 22019968 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current therapy at 40 Hz
Number of subjects: 60
Study 22019968 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current therapy at 100 Hz
Number of subjects: 60
Study 22019968 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current therapy at 180 Hz
Number of subjects: 60
Study 22019968 — intervention group
Group type: COMPARATOR
Intervention: Sham interferential current therapy
Number of subjects: 60
Study 22019968 — intervention group
Group type: EXPERIMENTAL
Intervention: All active IFC groups (40, 100, 180 Hz)
Number of subjects: 60
Study 22019968 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (active IFC and sham)
Number of subjects: 60
Study 18443874 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic operation (TEO) using standard endoscopic instruments with 2D visualization.
Number of subjects: 31
Study 17513706 — intervention group
Group type: EXPERIMENTAL
Intervention: AICAR
Number of subjects: 29
Study 17513706 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise
Number of subjects: 29
Study 15638046 — intervention group
Group type: EXPERIMENTAL
Intervention: 169Er-citrate
Number of subjects: 44
Study 15638046 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 44
Study 11427221 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 104
Study 9732339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control of blood pressure
Number of subjects: 1148
Study 9732339 — intervention group
Group type: COMPARATOR
Intervention: Less tight control of blood pressure
Number of subjects: 1148
Study 8305323 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream (single application)
Number of subjects: 99
Study 8305323 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream (3 days once-daily therapy)
Number of subjects: 99
Study 8305323 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream (5 days once-daily therapy)
Number of subjects: 99
Study 8305323 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream (7 days once-daily therapy)
Number of subjects: 99
Study 8305323 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream
Number of subjects: 99
Study 3385111 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard trivalent influenza vaccine (15 micrograms of B/USSR/100/83) + placebo
Number of subjects: 131
Study 3385111 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard trivalent vaccine (15 micrograms of B/USSR/100/83) + supplemental dose (45 micrograms of B/USSR)
Number of subjects: 131
Study 3385111 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental dose (45 micrograms of B/USSR) + placebo
Number of subjects: 131
Study 3385111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 31045894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 34
Study 31045894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg neostigmine/0.5 mg atropine (n = 11)
Number of subjects: 34
Study 31045894 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg sugammadex (n = 11)
Number of subjects: 34
Study 28431051 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line endoepicardial VT substrate ablation
Number of subjects: 41
Study 26132683 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct identification of OCD vignette
Number of subjects: 208
Study 26132683 — intervention group
Group type: EXPERIMENTAL
Intervention: Misidentification of OCD vignette
Number of subjects: 208
Study 26132683 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette type
Number of subjects: 208
Study 22773551 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus erlotinib
Number of subjects: 281
Study 22773551 — intervention group
Group type: COMPARATOR
Intervention: capecitabine plus erlotinib
Number of subjects: 281
Study 22773551 — intervention group
Group type: EXPERIMENTAL
Intervention: skin rash
Number of subjects: 281
Study 22773551 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS wild-type status
Number of subjects: 281
Study 21492030 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele
Number of subjects: 48
Study 21492030 — intervention group
Group type: COMPARATOR
Intervention: Comparison
Number of subjects: 48
Study 18725045 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy surgery
Number of subjects: 5
Study 16473371 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐IPT SPECT in PD patients
Number of subjects: 39
Study 16473371 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐IPT SPECT in PSP patients
Number of subjects: 39
Study 16473371 — intervention group
Group type: COMPARATOR
Intervention: Comparison of V3'' values between PD and PSP
Number of subjects: 39
Study 16473371 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of posterior putamen/caudate ratio in PD patients
Number of subjects: 39
Study 12880604 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nutrition supplement
Number of subjects: 68
Study 12880604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 10965617 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular assist system with blood drainage from the left ventricle (LV drainage Group)
Number of subjects: 13
Study 10965617 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular assist system with blood drainage from the left atrium (LA drainage Group)
Number of subjects: 13
Study 10965617 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 13
Study 9088996 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase treatment (10,000 U/m2 every 3-4 days)
Number of subjects: 0
Study 9088996 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli preparation Asparaginase medac (2500 U/m2)
Number of subjects: 0
Study 9088996 — intervention group
Group type: EXPERIMENTAL
Intervention: Erwinia preparation Erwinase
Number of subjects: 0
Study 8178703 — intervention group
Group type: EXPERIMENTAL
Intervention: schema (matrix/map)
Number of subjects: 111
Study 8178703 — intervention group
Group type: COMPARATOR
Intervention: nonschema (essay)
Number of subjects: 111
Study 2947108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (600 mg)
Number of subjects: 8
Study 2947108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29540131 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted National Diabetes Prevention Program (NDPP) with male-only groups and male coaches
Number of subjects: 0
Study 29540131 — intervention group
Group type: COMPARATOR
Intervention: Standard Diabetes Prevention Program (DPP)
Number of subjects: 0
Study 26968644 — intervention group
Group type: EXPERIMENTAL
Intervention: AQX-1125
Number of subjects: 69
Study 26968644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 24256139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 69
Study 24256139 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion
Number of subjects: 69
Study 22759081 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based home care (HBHC) for 6 days
Number of subjects: 60
Study 22759081 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based care
Number of subjects: 60
Study 22759081 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based home care (HBHC)
Number of subjects: 60
Study 20087332 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DES)
Number of subjects: 397
Study 20087332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 397
Study 20087332 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 397
Study 20087332 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 397
Study 18751626 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal perineal massage (10 minutes daily from 34 weeks of gestation until delivery)
Number of subjects: 234
Study 18751626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no perineal massage)
Number of subjects: 234
Study 16916298 — intervention group
Group type: EXPERIMENTAL
Intervention: Homapak (fixed-dose CQ+S/P combination)
Number of subjects: 32
Study 16916298 — intervention group
Group type: COMPARATOR
Intervention: Fansidar + CQ
Number of subjects: 32
Study 16916298 — intervention group
Group type: COMPARATOR
Intervention: Fansidar (Sulfadoxine alone)
Number of subjects: 32
Study 16916298 — intervention group
Group type: COMPARATOR
Intervention: GMP made drugs
Number of subjects: 32
Study 12562875 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (n-3 polyunsaturated fatty acids, DHA and EPA)
Number of subjects: 0
Study 12562875 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (docosahexaenoic acid)
Number of subjects: 0
Study 12562875 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid)
Number of subjects: 0
Study 12562875 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA and EPA
Number of subjects: 0
Study 12562875 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 0
Study 12562875 — intervention group
Group type: COMPARATOR
Intervention: Lauric acid (saturated fatty acid)
Number of subjects: 0
Study 10704627 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (E2) valerate, 2 mg/day
Number of subjects: 73
Study 10704627 — intervention group
Group type: COMPARATOR
Intervention: Transdermal E2 gel, 1 mg/day
Number of subjects: 73
Study 9356611 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 620
Study 9356611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 1493959 — intervention group
Group type: EXPERIMENTAL
Intervention: Information sheet and questionnaire provided to clients
Number of subjects: 0
Study 3933320 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 5778
Study 3933320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5778
Study 30952510 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid
Number of subjects: 201
Study 30952510 — intervention group
Group type: COMPARATOR
Intervention: Usual Counseling
Number of subjects: 201
Study 29297779 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership and Coping Enhancement Program (PCEP)
Number of subjects: 100
Study 29297779 — intervention group
Group type: COMPARATOR
Intervention: Routine care control group
Number of subjects: 100
Study 26446115 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine pathway
Number of subjects: 60
Study 26446115 — intervention group
Group type: COMPARATOR
Intervention: Traditional in-person care model
Number of subjects: 60
Study 24259265 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% cutaneous patch
Number of subjects: 1044
Study 22410103 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural support with a standard length reduction programme (34 weeks)
Number of subjects: 160
Study 22410103 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural support with a short length reduction programme (4 weeks)
Number of subjects: 160
Study 22410103 — intervention group
Group type: COMPARATOR
Intervention: No support with a standard length reduction programme (34 weeks)
Number of subjects: 160
Study 22410103 — intervention group
Group type: COMPARATOR
Intervention: No support with a short length reduction programme (4 weeks)
Number of subjects: 160
Study 22410103 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants encouraged to use NRT
Number of subjects: 160
Study 21059257 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-focused intervention approach
Number of subjects: 94
Study 21059257 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-focused intervention approach
Number of subjects: 94
Study 21059257 — intervention group
Group type: COMPARATOR
Intervention: Regular care intervention
Number of subjects: 94
Study 21059257 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 94
Study 21059257 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF-CY domains
Number of subjects: 94
Study 17927543 — intervention group
Group type: EXPERIMENTAL
Intervention: MMORPG
Number of subjects: 100
Study 17927543 — intervention group
Group type: COMPARATOR
Intervention: Arcade, Console, Solo Computer
Number of subjects: 100
Study 15181577 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent human/bovine reassortant rotavirus vaccine
Number of subjects: 439